Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design

被引：34

作者：

Garrido, Pilar ^{[1
]}

Pujol, Jean-Louis ^{[2
]}

Kim, Edward S. ^{[3
]}

Lee, Jay M. ^{[4
]}

Tsuboi, Masahiro ^{[5
]}

Gomez-Rueda, Ana ^{[1
]}

Benito, Amparo ^{[1
]}

Moreno, Nicolas ^{[1
]}

Gorospe, Luis ^{[1
]}

Dong, Tuochuan ^{[6
]}

Blin, Cecile ^{[7
]}

Rodrik-Outmezguine, Vanessa ^{[6
]}

Passos, Vanessa Q. ^{[6
]}

Mok, Tony S. K. ^{[8
]}

机构：

[1] Hosp Ramon & Cajal, Madrid 28034, Spain

[2] Hosp Arnaud Villeneuve, F-34090 Montpellier, France

[3] Atrium Hlth, Levine Canc Inst, Charlotte, NC 28202 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba 1120002, Japan

[6] Novartis Pharmaceut, E Hanover, NJ 07936 USA

[7] Novartis Pharma AG, CH-4056 Basel, Switzerland

[8] Chinese Univ Hong Kong, Hong Kong 999077, Peoples R China

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 12期

关键词：

canakinumab; CANOPY; early stage; immunotherapy; major pathological response; MPR; neoadjuvant; non-small-cell lung cancer; resection; surgery; NIVOLUMAB PLUS IPILIMUMAB; NEOADJUVANT ATEZOLIZUMAB; IL-1; FAMILY; PD-L1; EXPRESSION; RISK-FACTORS; SINGLE-ARM; OPEN-LABEL; CHEMOTHERAPY; SURVIVAL; INFLAMMATION;

D O I：

10.2217/fon-2020-1098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Canakinumab is a human IgG kappa monoclonal antibody, with high affinity and specificity for IL-1 beta. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial, evaluating canakinumab for cardiovascular disease, provided the first signal of the potential of IL-111 inhibition on lung cancer incidence reduction. Here, we describe the rationale and design for CANOPY-N, a randomized Phase II trial evaluating IL-1 beta inhibition with or without immune checkpoint inhibition as neoadjuvant treatment in patients with non-small-cell lung cancer. Patients with stage IB to IIIA non-small-cell lung cancer eligible for complete resection will receive canakinumab or pembrolizumab as monotherapy, or in combination. The primary end point is major pathological response by central review; secondary end points include overall response rate, major pathological response (local review), surgical feasibility rate and pharmacokinetics.

引用

页码：1459 / 1472

页数：14

共 62 条

[1] Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status [J].

Adachi, Yuichi ;

Tamiya, Akihiro ;

Taniguchi, Yoshihiko ;

Enomoto, Takatoshi ;

Azuma, Kouji ;

Kouno, Shunichi ;

Inagaki, Yuji ;

Saijo, Nobuhiko ;

Okishio, Kyoichi ;

Atagi, Shinji .

CANCER MEDICINE, 2020, 9 (04) :1383-1391

[2] Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers [J].

Akamine, Takaki ;

Takada, Kazuki ;

Toyokawa, Gouji ;

Kinoshita, Fumihiko ;

Matsubara, Taichi ;

Kozuma, Yuka ;

Haratake, Naoki ;

Takamori, Shinkichi ;

Hirai, Fumihiko ;

Tagawa, Tetsuzo ;

Okamoto, Tatsuro ;

Yoneshima, Yasuto ;

Okamoto, Isamu ;

Shimokawa, Mototsugu ;

Oda, Yoshinao ;

Nakanishi, Yoichi ;

Maehara, Yoshihiko .

SURGICAL ONCOLOGY-OXFORD, 2018, 27 (01) :88-94

[3] The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis [J].

Alten, Rieke ;

Gram, Hermann ;

Joosten, Leo A. ;

van den Berg, Wim B. ;

Sieper, Joachim ;

Wassenberg, Siegfrid ;

Burmester, Gerd ;

van Riel, Piet ;

Diaz-Lorente, Maria ;

Bruin, Gerardus Jm ;

Woodworth, Thasia G. ;

Rordorf, Christiane ;

Batard, Yannik ;

Wright, Andrew M. ;

Jung, Thomas .

ARTHRITIS RESEARCH & THERAPY, 2008, 10 (03)

[4] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[5]

Ardizzoni, 2019, ANN ONCOL, V30, pV602

[6] IL-1 Family Members in Cancer; Two Sides to Every Story [J].

Baker, Kevin J. ;

Houston, Aileen ;

Brint, Elizabeth .

FRONTIERS IN IMMUNOLOGY, 2019, 10

[7] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial [J].

Besse, B. ;

Adam, J. ;

Cozic, N. ;

Chaput-Gras, N. ;

Planchard, D. ;

Mezquita, L. ;

Remon Masip, J. ;

Lavaud, P. ;

Naltet, C. ;

Gazzah, A. ;

de Montpreville, V. Thomas ;

Ghigna, M. -R. ;

Mussot, S. ;

Fadel, E. ;

Mabille, L. ;

Duchemann, B. ;

Barlesi, F. ;

Soria, J-C. ;

Caramella, C. ;

Mercier, O. .

ANNALS OF ONCOLOGY, 2020, 31 :S794-S795

[8] Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer [J].

Blumenthal, Gideon M. ;

Bunn, Paul A., Jr. ;

Chaft, Jamie E. ;

McCoach, Caroline E. ;

Perez, Edith A. ;

Scagliotti, Giorgio V. ;

Carbone, David P. ;

Aerts, Hugo J. W. L. ;

Aisner, Dara L. ;

Bergh, Jonas ;

Berry, Donald A. ;

Jarkowski, Anthony ;

Botwood, Nicholas ;

Cross, Darren A. E. ;

Diehn, Max ;

Drezner, Nicole L. ;

Doebele, Robert C. ;

Blakely, Collin M. ;

Eberhardt, Wilfried E. E. ;

Felip, Enriqueta ;

Gianni, Luca ;

Keller, Steven P. ;

Leavey, Patrick J. ;

Malik, Shakun ;

Pignatti, Francesco ;

Prowell, Tatiana M. ;

Redman, Mary W. ;

Rizvi, Naiyer A. ;

Rosell, Rafael ;

Rusch, Valerie ;

de Ruysscher, Dirk ;

Schwartz, Lawrence H. ;

Sridhara, Rajeshwari ;

Stahel, Rolf A. ;

Swisher, Stephen ;

Taube, Janis M. ;

Travis, William D. ;

Keegan, Patricia ;

Wiens, Jacinta R. ;

Wistuba, Ignacio I. ;

Wynes, Murry W. ;

Hirsch, Fred R. ;

Kris, Mark G. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) :1818-1831

[9] The Role of IL-1β in the Early Tumor Cell-Induced Angiogenic Response [J].

Carmi, Yaron ;

Dotan, Shahar ;

Rider, Peleg ;

Kaplanov, Irena ;

White, Malka R. ;

Baron, Rona ;

Abutbul, Shai ;

Huszar, Monica ;

Dinarello, Charles A. ;

Apte, Ron N. ;

Voronov, Elena .

JOURNAL OF IMMUNOLOGY, 2013, 190 (07) :3500-3509

[10]

Cascone T, 2019, J CLIN ONCOL, V37

← 1 2 3 4 5 6 7 →